ArticleTheranostics2020
Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Tumor microenvironment and signaling pathways in melanoma brain metastasis.Annals of translational medicine · 2026Review
- BASP1 promotes breast cancer progression and shapes an immunosuppressive microenvironment by recruiting MDSCs and suppressing T cell function.Human cell · 2026Article
- Future directions in the treatment of brain metastases: evaluating the role of cellular players in the tumour microenvironment.Acta neuropathologica · 2026Review
- ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Reactivation of the silencedProceedings of the National Academy of Sciences of the United States of America · 2026Article
- A CMTM6 Nanobody Overcomes EGFR-TKI Resistance in Non-Small Cell Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Multiprobe Photoproximity Labeling of the EGFR Interactome in Glioblastoma Using Red-Light.Journal of the American Chemical Society · 2025Article
- A comprehensive analysis of molecular characteristics of hot and cold tumor of gastric cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Comparative profiling of whole-cell and exosome samples reveals protein signatures that stratify breast cancer subtypes.Cellular and molecular life sciences : CMLS · 2024Article
- Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy.Nature cancer · 2024Article
- ADAM9 drives the immunosuppressive microenvironment by cholesterol biosynthesis-mediated activation of IL6-STAT3 signaling for lung tumor progression.American journal of cancer research · 2024Article
- Proteomics-based Model for Predicting the Risk of Brain Metastasis in Patients with Resected Lung Adenocarcinoma carrying the EGFR Mutation.International journal of medical sciences · 2024Article
- Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.Molecular cancer · 2023Article
- Review
- Inhibition of CDCP1 by 8-isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment.Molecular oncology · 2023Article
- BASP1 expression is associated with poor prognosis and is correlated with immune infiltration in gastric cancer.FEBS open bio · 2023Article
- BASP1 promotes high glucose-induced endothelial apoptosis in diabetes via activation of EGFR signaling.Journal of diabetes investigation · 2023Article
- Cellular Transcriptomics of Carboplatin Resistance in a Metastatic Canine Osteosarcoma Cell Line.Genes · 2023Article
- BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma.Frontiers in oncology · 2023Article
- Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis.International journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 3 countries.
Ching-Chan LinGraduate Institute of Clinical Medical Science, China Medical University, Taichung 404, Taiwan.
Yu-Kai HuangGraduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.
Chia-Fong ChoCenter for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Yu-Sen LinGraduate Institute of Clinical Medical Science, China Medical University, Taichung 404, Taiwan.
Chia-Chien LoCenter for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Ting-Ting KuoCenter for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Guan-Chin TsengDepartment of Anatomic Pathology, Nantou Hospital of the Ministry of Health and Welfare, Nantou 540, Taiwan.
Wei-Chung ChengGraduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.
Wei-Chao ChangCenter for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Tzu-Hung HsiaoDepartment of Medical Research, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Liang-Chuan LaiGraduate Institute of Physiology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Jin-Yuan ShihGraduate Institute of Clinical Medicine, National Taiwan University, Taipei 106, Taiwan.
Yu-Huei LiuGraduate Institute of Integrated Medicine, China Medical University, Taichung 404, Taiwan.
K S Clifford ChaoCancer Center, China Medical University Hospital, Taichung 404, Taiwan.
Jennifer L HsuDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Pei-Chih LeeGraduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.
Xian SunDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Mien-Chie HungGraduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.
Yuh-Pyng SherGraduate Institute of Clinical Medical Science, China Medical University, Taichung 404, Taiwan.
China Medical University Hospital · TWChina Medical University · TWHarbin Medical University · CNNational Taiwan University · TWNational Taiwan University Hospital · TWTaichung Veterans General Hospital · TWThe University of Texas MD Anderson Cancer Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adenocarcinoma of LungAnimalsAntineoplastic Combined Chemotherapy ProtocolsArsenic TrioxideBrainBrain NeoplasmsCell Line, TumorCell MembraneDrug Resistance, NeoplasmErbB ReceptorsFeedback, PhysiologicalGene Expression ProfilingGene Knockdown TechniquesHumansKaplan-Meier EstimateLungArsenic TrioxideBASP1 protein, humanEGFR protein, humanErbB ReceptorsMembrane ProteinsNerve Tissue ProteinsProtein Kinase InhibitorsRepressor Proteinsarsenic trioxideBASP1combination therapyEGFR-TKI acquired resistancelung adenocarcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.